BioPharmSignal logoBioPharmSignal

Company Profile

Voyager Therapeutics Stock Price, News & Catalysts

Ticker:
VYGR
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

3.04 USD (-0.33%)

Close

Last updated: September 17, 2026

217M USD

Market cap

Why the stock is moving

As of Sep 17, 2026, VYGR closed down 0.33% at $3.04. No new same-company headline was identified in the current news window.

Company overview

Neurologic Genetic Medicines

Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology. Its pipeline includes wholly owned and partnered programs.

TRACER Capsid Platform

The TRACER platform discovers adeno-associated-virus capsids designed to reach the central nervous system after intravenous dosing. These capsids support gene-replacement and gene-silencing programs.

Tau-Directed Alzheimer's Programs

VY1706 is a tau-silencing gene therapy approaching clinical development, while VY7523 is an anti-tau antibody already undergoing clinical evaluation in Alzheimer's disease.

Partnered Friedreich's Ataxia Program

NBIB-223 is a Neurocrine-partnered gene therapy for Friedreich's ataxia that has completed IND-enabling toxicology.

Future catalysts

  • IND application process for VY1706 in the second quarter of 2026.
  • First-in-human dosing of VY1706 in Alzheimer's disease in the second half of 2026.
  • Tau PET imaging efficacy data from the VY7523 study in the second half of 2026.
  • Initiation of a clinical trial of NBIB-223 in Friedreich's ataxia in the second half of 2026, pending IND clearance.

Recent news

  1. 01

    Voyager to Present at Upcoming Investor Conferences

  2. 02

    Voyager Reports Second Quarter 2026 Financial and Operating Results

  3. 03

    Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

  4. 04

    Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

  5. 05

    Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

TSHA

Taysha Gene Therapies

BLUE

bluebird bio, Inc.

CING

Cingulate Inc.

SLDB

Solid Biosciences

GBIO

Generation Bio

BLFS

BioLife Solutions

FIXX

Homology Medicines

GNPX

Genprex

Frequently Asked Questions

What is the current stock price of Voyager Therapeutics (VYGR)?

Voyager Therapeutics (VYGR) most recently closed at 3.04 USD, a -0.33% move versus the previous session.

What is the market cap of Voyager Therapeutics (VYGR)?

Voyager Therapeutics currently has a market capitalization of 217M USD on BioPharmSignal.

What does Voyager Therapeutics do?

Neurologic Genetic Medicines Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology. Its pipeline includes wholly owned and partnered programs. TRACER Capsid Platform The TRACER platform discovers adeno-associated-virus capsids designed to reach the central nervous system after intravenous...

On which exchange is VYGR stock listed?

Voyager Therapeutics (VYGR) is associated with NASDAQ, United States, Biopharma.

What is NBIB-223?

Initiation of a clinical trial of NBIB-223 in Friedreich's ataxia in the second half of 2026, pending IND clearance.

Which conditions is Voyager Therapeutics targeting with NBIB-223?

Voyager Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.

How does Voyager Therapeutics describe recent progress with NBIB-223?

Initiation of a clinical trial of NBIB-223 in Friedreich's ataxia in the second half of 2026, pending IND clearance.

What is Neurologic?

Neurologic Genetic Medicines Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology.